Brachytherapy Stents Using 125Iodine for Lung Cancer Associated with Superior Vena Cava Syndrome - Takeaways - MDSpire

Brachytherapy Stents Using 125Iodine for Lung Cancer Associated with Superior Vena Cava Syndrome

  • By

  • Yipu Li

  • Zhanguo Sun

  • Haotian Duan

  • Mengyao Song

  • Rongna Hou

  • Xinwei Han

  • Yan Yan

  • Dechao Jiao

  • March 4, 2026

  • 0 min

Share

  • 1

    Superior vena cava syndrome (SVCS) is primarily caused by malignant tumors, necessitating multidisciplinary treatment approaches.

  • 2

    SVC stenting is a preferred intervention for SVCS, but tumor ingrowth can lead to reobstruction and recurrence of symptoms.

  • 3

    Radioactive 125Iodine seeds implantation has shown promising local control rates in various cancers, including lung cancer.

  • 4

    A new brachytherapy stent combining 125Iodine seeds with self-expandable metallic stents (SEMS) has been developed for SVCS treatment.

  • 5

    This study included 76 patients, comparing conventional SVC stenting with the new brachytherapy stent approach for SVCS.

Original Source(s)

Brachytherapy Stents Using 125Iodine for Lung Cancer Associated with Superior Vena Cava Syndrome

  • by Yipu Li, Zhanguo Sun, Haotian Duan, Mengyao Song, Rongna Hou, Xinwei Han, Yan Yan, Dechao Jiao

  • March 4, 2026

Related Content

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer